Showing 1 - 10 of 10
Persistent link: https://www.econbiz.de/10012536347
Persistent link: https://www.econbiz.de/10012280570
Persistent link: https://www.econbiz.de/10012280573
It is widely accepted proposition that one of the aims of the UK National Health Service is to allocate health care on the basis of need. However, while there may be considerable consensus over the legitimacy of this goal, there is also considerable debate as to whether the goal has been met. If...
Persistent link: https://www.econbiz.de/10005547882
This review examines the performance of the UK healthcare system. After presenting data on the level and distribution of resources, three topics are examined. The first is the lessons from international comparisons of evidence on expenditure, equity and healthcare outcomes. The second is the...
Persistent link: https://www.econbiz.de/10005509366
It is common to analyse poverty data broken down by household or economic status. Implicitly, it is assumed that people change state (for example, single, married, children, no children) for exogenous reasons. If we bring economic behaviour into the problem, then such transitions become...
Persistent link: https://www.econbiz.de/10005811357
A long-standing concern surrounding the performance of the UK economy is its perceived failure to maintain the same technological pace as its competitors. Industrial research and development (R&D) expenditure as a proportion of GDP fell during the 1980s at a time when all other G7 countries...
Persistent link: https://www.econbiz.de/10005547827
This paper concerns the new economy (alias the knowledge-based economy). I examine the different meanings attached to the new economy term and the evidence surrounding it, concentrating on the upsurge in US productivity growth between 1995 and 2000. I argue that the reports of the death of the...
Persistent link: https://www.econbiz.de/10005509364
This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK, NHS pharmaceutical expenditures on branded drugs, currently worth about £3 billion a year, have been regulated by the Pharmaceutical Price Regulation Scheme (PPRS) since 1978. We argue that, in...
Persistent link: https://www.econbiz.de/10005811257
This paper investigates the economic impact of the government’s proposed new UK R&D tax credit. We measure the benefit of the credit by the effect on value added in the short and long runs. This is simulated from existing econometric estimates of the tax-price elasticity of research and...
Persistent link: https://www.econbiz.de/10005811278